AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34767481 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard SICs without nudges)
Number of subjects: 14607
Study 34684084 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine for 30 days
Number of subjects: 56
Study 34684084 — intervention group
Group type: COMPARATOR
Intervention: Control group (no colchicine)
Number of subjects: 56
Study 35274859 — intervention group
Group type: EXPERIMENTAL
Intervention: BESTFertil for 3 months
Number of subjects: 63
Study 35274859 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BESTFertil)
Number of subjects: 63
Study 33448007 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EG, n = 34)
Number of subjects: 66
Study 33448007 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n = 32)
Number of subjects: 66
Study 35513855 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised computerised cognitive training (MAKSCog) for 6 months
Number of subjects: 0
Study 35513855 — intervention group
Group type: COMPARATOR
Intervention: Basic computerised cognitive training (active control)
Number of subjects: 0
Study 33079329 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation (n=79)
Number of subjects: 143
Study 33079329 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=82)
Number of subjects: 143
Study 33079329 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 143
Study 33019837 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 46)
Number of subjects: 312
Study 33019837 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical shortening without funneling (n = 107)
Number of subjects: 312
Study 33019837 — intervention group
Group type: EXPERIMENTAL
Intervention: V‐shaped funneling (n = 68)
Number of subjects: 312
Study 33019837 — intervention group
Group type: EXPERIMENTAL
Intervention: U‐shaped funneling (n = 47)
Number of subjects: 312
Study 33019837 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolapse of the amniotic sac (n = 44)
Number of subjects: 312
Study 32176574 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol portrayals (yes)
Number of subjects: 90
Study 32176574 — intervention group
Group type: COMPARATOR
Intervention: Alcohol portrayals (no)
Number of subjects: 90
Study 32176574 — intervention group
Group type: EXPERIMENTAL
Intervention: Ego depletion (no)
Number of subjects: 90
Study 32176574 — intervention group
Group type: COMPARATOR
Intervention: Ego depletion (yes)
Number of subjects: 90
Study 35279508 — intervention group
Group type: EXPERIMENTAL
Intervention: SLN biopsy only
Number of subjects: 1181
Study 35279508 — intervention group
Group type: COMPARATOR
Intervention: Completion ALND
Number of subjects: 1181
Study 32230721 — intervention group
Group type: EXPERIMENTAL
Intervention: Robuvit® (300 mg/day) for 4 weeks
Number of subjects: 0
Study 32230721 — intervention group
Group type: EXPERIMENTAL
Intervention: Robuvit®
Number of subjects: 0
Study 32230721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33399514 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Laryngeal Force Sensor (LFS) monitoring
Number of subjects: 200
Study 33399514 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active LFS monitoring)
Number of subjects: 200
Study 32375613 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (VCR-reducing therapy)
Number of subjects: 75
Study 36175977 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated mental health care and vocational rehabilitation (IBBIS-II)
Number of subjects: 900
Study 36175977 — intervention group
Group type: COMPARATOR
Intervention: Service as usual (SAU)
Number of subjects: 900
Study 34235560 — intervention group
Group type: EXPERIMENTAL
Intervention: Eluvia DES
Number of subjects: 84
Study 34235560 — intervention group
Group type: COMPARATOR
Intervention: Zilver PTX drug-coated stent
Number of subjects: 84
Study 32102239 — intervention group
Group type: EXPERIMENTAL
Intervention: MCA stroke participants
Number of subjects: 7
Study 32102239 — intervention group
Group type: COMPARATOR
Intervention: Control group (25 neurotypical adult males)
Number of subjects: 7
Study 36208795 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted detection (CADe)
Number of subjects: 223
Study 36208795 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy
Number of subjects: 223
Study 34671454 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 20
Study 34671454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 32921388 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions for OLP treatment (specific interventions not detailed in the abstract)
Number of subjects: 88
Study 32921388 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical symptom assessment
Number of subjects: 88
Study 32921388 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical score assessment
Number of subjects: 88
Study 32921388 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analog scale
Number of subjects: 88
Study 32921388 — intervention group
Group type: EXPERIMENTAL
Intervention: Thongprasom scoring system
Number of subjects: 88
Study 32921388 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health-related quality of life measures
Number of subjects: 88
Study 35963234 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination strategies for recovered inpatients with COVID-19
Number of subjects: 0
Study 33417279 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐IOD (single midline implant)
Number of subjects: 47
Study 33417279 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐IOD (two implants in the canine regions bilaterally)
Number of subjects: 47
Study 33417279 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐IOD
Number of subjects: 47
Study 33417279 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐IOD
Number of subjects: 47
Study 32861144 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART treatment for 48 weeks
Number of subjects: 0
Study 32861144 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART treatment for 48 weeks in low microbial translocation (MT) group
Number of subjects: 0
Study 32861144 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART treatment for 48 weeks in high microbial translocation (MT) group
Number of subjects: 0
Study 33300437 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized antiplatelet therapy based on CYP2C19 genotyping (IA group)
Number of subjects: 0
Study 33300437 — intervention group
Group type: COMPARATOR
Intervention: Conventional antiplatelet therapy (CA group)
Number of subjects: 0
Study 34680732 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm I (data-based feedback and quality circles)
Number of subjects: 196
Study 34680732 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm II (data-based feedback, quality circles, and additional components)
Number of subjects: 196
Study 34680732 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm III (data-based feedback, quality circles, and different additional components)
Number of subjects: 196
Study 34680732 — intervention group
Group type: EXPERIMENTAL
Intervention: All intervention arms (I, II, III)
Number of subjects: 196
Study 34680732 — intervention group
Group type: COMPARATOR
Intervention: Matched standard care
Number of subjects: 196
Study 33608465 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette use
Number of subjects: 0
Study 33608465 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette use among 15-24 years age group
Number of subjects: 0
Study 33608465 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette use and smoking cessation
Number of subjects: 0
Study 35513910 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic (Vivomixx®) 4.4 g/day for 4 weeks
Number of subjects: 59
Study 35513910 — intervention group
Group type: COMPARATOR
Intervention: Non-probiotic milk-powder placebo 4.4 g/day for 4 weeks
Number of subjects: 59
Study 33213193 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 0
Study 33213193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 616533255 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (15°C for 5 minutes)
Number of subjects: 20
Study 34550476 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision approach
Number of subjects: 40
Study 34550476 — intervention group
Group type: COMPARATOR
Intervention: Double-incision approach
Number of subjects: 40
Study 32761373 — intervention group
Group type: EXPERIMENTAL
Intervention: One anastomosis gastric bypass (OAGB)
Number of subjects: 33
Study 32761373 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 33
Study 32761373 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OAGB and RYGB
Number of subjects: 33
Study 33890158 — intervention group
Group type: COMPARATOR
Intervention: Concurrent training (PAR)
Number of subjects: 67
Study 35938554 — intervention group
Group type: EXPERIMENTAL
Intervention: Hughes abdominal closure
Number of subjects: 802
Study 35938554 — intervention group
Group type: COMPARATOR
Intervention: Standard mass closure
Number of subjects: 802
Study 35938554 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography scanning
Number of subjects: 802
Study 35938554 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 802
Study 33070947 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT-Core model
Number of subjects: 26228
Study 33070947 — intervention group
Group type: EXPERIMENTAL
Intervention: CRASH-Basic model
Number of subjects: 26228
Study 33070947 — intervention group
Group type: EXPERIMENTAL
Intervention: Both models
Number of subjects: 26228
Study 36399673 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily for three weeks
Number of subjects: 120
Study 36399673 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily for three weeks
Number of subjects: 120
Study 32325265 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugation + 1-day inoculation
Number of subjects: 44
Study 32325265 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugation + 14-day inoculation
Number of subjects: 44
Study 32325265 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary inoculation + 1-day
Number of subjects: 44
Study 32325265 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary inoculation + 14-day
Number of subjects: 44
Study 34046741 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic liability to periodontitis (measured using six SNPs associated with periodontitis)
Number of subjects: 17353
Study 34046741 — intervention group
Group type: EXPERIMENTAL
Intervention: Replication analysis using genetic instruments from two different GWAS
Number of subjects: 17353
Study 32027842 — intervention group
Group type: EXPERIMENTAL
Intervention: m102.4 (1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg)
Number of subjects: 40
Study 32027842 — intervention group
Group type: EXPERIMENTAL
Intervention: m102.4 (20 mg/kg, two infusions 72 hours apart)
Number of subjects: 40
Study 32027842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 32027842 — intervention group
Group type: EXPERIMENTAL
Intervention: m102.4
Number of subjects: 40
Study 35477745 — intervention group
Group type: EXPERIMENTAL
Intervention: tsDCS + LT
Number of subjects: 8
Study 35477745 — intervention group
Group type: COMPARATOR
Intervention: sham + LT
Number of subjects: 8
Study 33326481 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational learning with a model introduced as another participant
Number of subjects: 0
Study 33326481 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational learning with a model introduced as a coworker of the experimenter
Number of subjects: 0
Study 33326481 — intervention group
Group type: COMPARATOR
Intervention: Control group with no observation
Number of subjects: 0
Study 32159592 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic patients (moderate and severe)
Number of subjects: 135
Study 32159592 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic patients
Number of subjects: 135
Study 32159592 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild symptomatic patients
Number of subjects: 135
Study 32159592 — intervention group
Group type: EXPERIMENTAL
Intervention: Contiguous symptomatic subgroups
Number of subjects: 135
Study 34486653 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 1988
Study 34486653 — intervention group
Group type: COMPARATOR
Intervention: CRT-P
Number of subjects: 1988
Study 32924183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) training for PHNs
Number of subjects: 6
Study 35149322 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with prescription OUD
Number of subjects: 36
Study 35149322 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 36
Study 32828931 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CTx)
Number of subjects: 249
Study 35059838 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic surgery
Number of subjects: 362
Study 35059838 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 362
Study 33858369 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of immunosuppression after diagnosis of HuNoV infection; 93% of cases experienced this intervention.
Number of subjects: 72
Study 33858369 — intervention group
Group type: EXPERIMENTAL
Intervention: HuNoV infection; cases vs controls
Number of subjects: 72
Study 32717421 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating miR‐21 levels in DCM group
Number of subjects: 266
Study 32717421 — intervention group
Group type: EXPERIMENTAL
Intervention: miR‐21 combined with duration of diabetes, HbA1c%, and lipid profiles
Number of subjects: 266
Study 32717421 — intervention group
Group type: EXPERIMENTAL
Intervention: Overexpression of miR‐21
Number of subjects: 266
Study 32717421 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of miR‐21
Number of subjects: 266
Study 36175576 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ; 12.8 mmol NO3‐)
Number of subjects: 10
Study 36175576 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study 33517703 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum complement C3 levels
Number of subjects: 3474
Study 33517703 — intervention group
Group type: EXPERIMENTAL
Intervention: Each SD increase of log-transformed complement C3
Number of subjects: 3474
Study 33517703 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of serum complement C3 to conventional risk factors
Number of subjects: 3474
Study 32487157 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop-Tabac smartphone application
Number of subjects: 5200
Study 32706921 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic metformin ER tablets
Number of subjects: 4
Study 32706921 — intervention group
Group type: COMPARATOR
Intervention: Branded metformin ER tablets
Number of subjects: 4
Study 34895119 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid treatment (5 mg daily for 3 months)
Number of subjects: 113
Study 34895119 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 113
Study 32500344 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant transcatheter arterial infusion therapy (TAI)
Number of subjects: 114
Study 32500344 — intervention group
Group type: COMPARATOR
Intervention: Hepatectomy alone (Control)
Number of subjects: 114
Study 32500344 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant TAI for lower-cholinesterase patients
Number of subjects: 114
Study 36190577 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention with two healthy dietary approaches
Number of subjects: 0
Study 34078808 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited-point plasma concentration analysis of CYP substrates in a cocktail drug
Number of subjects: 0
Study 33154071 — intervention group
Group type: EXPERIMENTAL
Intervention: Total NAA (tNAA)/total Cr (tCr) in normal-appearing WM
Number of subjects: 119
Study 33154071 — intervention group
Group type: EXPERIMENTAL
Intervention: Total NAA (tNAA) and tNAA/tCr in normal-appearing WM
Number of subjects: 119
Study 33154071 — intervention group
Group type: EXPERIMENTAL
Intervention: mIns/tCr in normal-appearing WM
Number of subjects: 119
Study 33154071 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Cho (tCho) in GM
Number of subjects: 119
Study 34014046 — intervention group
Group type: EXPERIMENTAL
Intervention: Average volume-assured pressure support (AVAPS) mode
Number of subjects: 60
Study 34014046 — intervention group
Group type: COMPARATOR
Intervention: Bilevel positive airway pressure-spontaneous/timed (BPAP-S/T) mode
Number of subjects: 60
Study 36333015 — intervention group
Group type: EXPERIMENTAL
Intervention: AI‐ECG algorithm notification
Number of subjects: 11573
Study 36333015 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 11573
Study 32964377 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Number of subjects: 0
Study 32964377 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy
Number of subjects: 0
Study 33909659 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM + STRONTIUM (10% strontium chloride + PBM)
Number of subjects: 50
Study 33909659 — intervention group
Group type: COMPARATOR
Intervention: Placebo + PBM
Number of subjects: 50
Study 33909659 — intervention group
Group type: EXPERIMENTAL
Intervention: STRONTIUM (10% strontium chloride)
Number of subjects: 50
Study 33909659 — intervention group
Group type: COMPARATOR
Intervention: PLACEBO (placebo gel + simulation of PBM)
Number of subjects: 50
Study 32267191 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncology subspecialty trials
Number of subjects: 1340
Study 32267191 — intervention group
Group type: EXPERIMENTAL
Intervention: Infertility/andrology subspecialty trials
Number of subjects: 1340
Study 32267191 — intervention group
Group type: EXPERIMENTAL
Intervention: Device trials
Number of subjects: 1340
Study 32267191 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination funding by industry/government/grants
Number of subjects: 1340
Study 32267191 — intervention group
Group type: COMPARATOR
Intervention: Clinical trials in AUA sections
Number of subjects: 1340
Study 32267191 — intervention group
Group type: COMPARATOR
Intervention: Failed trials
Number of subjects: 1340
Study 616627663 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34315331 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 263
Study 34315331 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 263
Study 34315331 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab, Secukinumab, Guselkumab, Ixekizumab, Brodalumab
Number of subjects: 263
Study 35982449 — intervention group
Group type: COMPARATOR
Intervention: Margarine without TFA (wTFA control group with 0.4 g TFA per 100 g margarine)
Number of subjects: 42
Study 35982449 — intervention group
Group type: EXPERIMENTAL
Intervention: Margarine with iTFA (iTFA group with 4.1 g TFA per 100 g margarine)
Number of subjects: 42
Study 35982449 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter with rTFA (rTFA group with 6.3 g TFA per 100 g butter)
Number of subjects: 42
Study 32702252 — intervention group
Group type: EXPERIMENTAL
Intervention: HEA-enriched Cordyceps cicadae mycelium (1.05 g granules once a day for 3 months)
Number of subjects: 49
Study 35372614 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual health counseling based on cognitive-behavioral therapy (CBT), 8 sessions of 90 minutes each
Number of subjects: 52
Study 35372614 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 52
Study 34029707 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended infusion (EI) of piperacillin/tazobactam (PTZ) at 100 mg/kg intravenously every 8 h for 4 hours
Number of subjects: 90
Study 34029707 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus (IB) of piperacillin/tazobactam (PTZ) at 100 mg/kg intravenously every 8 h for 30 minutes
Number of subjects: 90
Study 34029707 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended infusion (EI)
Number of subjects: 90
Study 34029707 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus (IB)
Number of subjects: 90
Study 32574418 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin and Albumin
Number of subjects: 0
Study 32574418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33227175 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0
Study 33227175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32441811 — intervention group
Group type: EXPERIMENTAL
Intervention: Swanson's Care
Number of subjects: 104
Study 34254966 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory Adaptation Training (SAT)
Number of subjects: 49
Study 34254966 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 49
Study 36293765 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11+ intervention for 8 weeks
Number of subjects: 20
Study 36293765 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 20
Study 33858620 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (280 mg single infusion)
Number of subjects: 199
Study 33858620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 33784350 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 0
Study 33784350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32731960 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy with mobilization (CM) twice per week for 5 weeks
Number of subjects: 60
Study 32731960 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy with mobilization plus home stretching exercises (CMS) 5 times per week for 5 weeks
Number of subjects: 60
Study 34059149 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly derived spot urine equation
Number of subjects: 768
Study 34059149 — intervention group
Group type: COMPARATOR
Intervention: Tanaka equation
Number of subjects: 768